Retatrutide is expected to receive FDA approval in 2027. The most probable window is mid-2027 if Eli Lilly files the New Drug Application in late 2026 and the FDA grants priority review, or late 2027 if the review proceeds on standard timelines. A 2026 approval is not realistic given the remaining Phase III TRIUMPH readouts and the compilation time required before an NDA submission.
The critical gating item is the cardiovascular outcomes trial, TRIUMPH-3, which is the longest in the program. Other TRIUMPH trials (obesity, diabetes, obstructive sleep apnea, hepatic endpoints) are expected to read out through 2026. Eli Lilly has not publicly disclosed a target filing date, but analyst consensus based on the trial schedule points to late 2026.
This article walks through the regulatory pathway from where retatrutide stands today to the expected approval decision, the specific catalysts that will move the timeline forward or back, and how the FDA process for retatrutide is likely to compare with recent class approvals for Wegovy and Zepbound.
Where retatrutide stands with the FDA today
As of April 2026, retatrutide (LY3437943) is an investigational drug. It has not been submitted to the FDA for approval. It is not available through legitimate prescription or compounding channels. The only lawful route to receiving retatrutide in the US is enrolment in one of the ongoing Phase III TRIUMPH trials, several of which are still enrolling participants at ClinicalTrials.gov- listed sites.
The FDA drug approval pathway for new molecular entities proceeds through four stages: preclinical, Phase I (safety and pharmacokinetics), Phase II (dose finding and initial efficacy), and Phase III (pivotal efficacy and safety). Retatrutide is mid-way through Phase III, with the first of eight trials (TRIUMPH-4) having read out in December 2025.
After Phase III completes, the sponsor compiles and submits an NDA, which typically takes three to six months. The FDA then reviews the NDA under either standard (ten-month) or priority (six-month) timelines. Priority review is granted when the drug offers a meaningful advance over approved therapies. For the efficacy background that underpins the priority review case, see the Retatrutide Clinical Trial Results article.
What the Phase III schedule tells us about the approval date
Eli Lilly runs eight trials under the TRIUMPH banner, each studying retatrutide in a different population or comorbidity. TRIUMPH-4 (obesity with knee osteoarthritis) was the first to read out in December 2025. The other seven readouts are expected through 2026, with the cardiovascular outcomes trial (TRIUMPH-3) running longest.
| Trial | Population | Status |
|---|---|---|
| TRIUMPH-1 | Obesity (general) | Readout expected 2026 |
| TRIUMPH-2 | Obesity + type 2 diabetes | Readout expected 2026 |
| TRIUMPH-3 | Cardiovascular outcomes | Longest trial, 2026–2027 |
| TRIUMPH-4 | Obesity + knee OA | Read out Dec 2025 |
| TRIUMPH-5 | Obstructive sleep apnea | Readout expected 2026 |
Registry numbers include NCT05882045 (TRIUMPH-1), NCT05929066 (TRIUMPH-2), and NCT06662383 (TRIUMPH-3) on ClinicalTrials.gov. Current enrolment status and estimated completion dates are maintained on the registry.
The NDA does not require every trial to have read out before submission. Lilly can file the obesity NDA on the basis of TRIUMPH-1, TRIUMPH-4, and supporting data, with TRIUMPH-2 and TRIUMPH-3 supporting subsequent diabetes and cardiovascular indications. This modular filing approach is what shaped the tirzepatide pathway, where Mounjaro (diabetes, May 2022) and Zepbound (obesity, November 2023) received separate approvals on separate tracks.
Filing timeline and catalysts
The realistic filing sequence works out as follows. Phase III obesity readouts complete in 2026. Lilly compiles the NDA over three to six months, placing a submission in late 2026 or early 2027. The FDA accepts the NDA for filing within 60 days and sets a PDUFA (Prescription Drug User Fee Act) action date at either six or ten months from acceptance, depending on review designation. This produces the mid-2027 to late-2027 approval window.
Priority review is plausible here. The FDA granted it to Wegovy for obesity on the basis of semaglutide's STEP 1 data (14.9% weight loss). Retatrutide's TRIUMPH-4 result (28.7% at 12mg) is a larger advance over the standard of care than semaglutide was at its approval. That said, priority review decisions depend on factors beyond the efficacy headline, so assume standard review as the base case and treat priority review as an upside scenario.
Three catalysts could delay the expected timeline. First, a safety signal in the remaining TRIUMPH readouts, particularly escalation of the dysesthesia finding or a cardiovascular concern emerging from TRIUMPH-3. The full safety breakdown is covered in Retatrutide Side Effects. Second, a manufacturing issue identified during the FDA pre-approval inspection, which has derailed other biologics and could push the PDUFA date back by a quarter or more. Third, an FDA advisory committee meeting requesting additional data before action, which would add six to twelve months.
Comparison: timelines for semaglutide, tirzepatide, and retatrutide
Recent incretin-class approvals provide the template. The pattern: Phase III completion, NDA filing three to six months later, priority review, approval within approximately nine to eighteen months from filing.
| Drug (Brand) | Indication | FDA Approval |
|---|---|---|
| Semaglutide (Ozempic) | Type 2 diabetes | December 2017 |
| Semaglutide (Wegovy) | Obesity | June 2021 |
| Tirzepatide (Mounjaro) | Type 2 diabetes | May 2022 |
| Tirzepatide (Zepbound) | Obesity | November 2023 |
| Retatrutide (TBD) | Obesity (expected) | Mid to late 2027 |
The commercial implication matters for timing. Every quarter of delay pushes retatrutide's launch into a market where tirzepatide (Zepbound) and semaglutide (Wegovy) continue to capture patient volume. Lilly has strong incentive to file as soon as the obesity data package is complete rather than wait for every TRIUMPH trial to finish. That likely means an obesity-first filing in late 2026, with diabetes and cardiovascular indications following in 2027 and 2028. For the broader class positioning, see Retatrutide vs Tirzepatide.
Frequently asked questions
When will retatrutide be FDA approved?
The most likely window is 2027, based on Phase III TRIUMPH readouts continuing through 2026 and standard FDA review timelines. If Eli Lilly files the New Drug Application in late 2026, a priority review (six months) would put approval in mid-2027 and a standard review (ten months) in late 2027. A 2026 approval is not realistic given the remaining trial schedule.
Has Eli Lilly submitted an NDA for retatrutide?
No. As of April 2026, the NDA has not been submitted. The company has not publicly disclosed a target filing date. Analyst consensus points to late 2026 or early 2027 based on when the cardiovascular outcomes trial and the remaining TRIUMPH readouts are expected to complete.
Will retatrutide qualify for FDA priority review?
Likely yes. Priority review is given to drugs that offer meaningful advances over existing approved treatments. Retatrutide's 28.7% weight loss at 12mg exceeds the approved class (tirzepatide at 22.5%, semaglutide at 14.9%). Wegovy received priority review for obesity, setting the precedent. Priority review compresses FDA evaluation from 10 months to six.
What could delay FDA approval of retatrutide?
Three main risks: a serious safety signal emerging in the remaining TRIUMPH readouts (particularly dysesthesia escalation or cardiovascular signal), manufacturing issues during the pre-approval inspection, or an FDA advisory committee requesting additional data. The cardiovascular outcomes trial (TRIUMPH-3) is the longest trial in the program and its result is the main gating item.
Will retatrutide be approved for both obesity and diabetes?
The initial NDA is expected to cover obesity (chronic weight management), mirroring the Wegovy and Zepbound pathway. A separate approval for type 2 diabetes would follow based on TRIUMPH-2 data, similar to how tirzepatide received Mounjaro (diabetes) and Zepbound (obesity) approvals on separate tracks. Both indications are likely within 12 months of each other.
What brand name will retatrutide use?
Eli Lilly has not announced a brand name as of April 2026. Tirzepatide uses Mounjaro for diabetes and Zepbound for obesity. The brand name is typically disclosed 6-12 months before expected launch and requires FDA review for avoiding medication confusion.
Will retatrutide be available internationally before or after FDA approval?
The EMA (Europe) and MHRA (UK) review processes run in parallel with the FDA but on different timelines. Approvals typically arrive within 12 months of each other. Eli Lilly has historically prioritised the US launch for incretin products, with European and UK rollout following within a year. Availability outside approved markets will be limited by manufacturing capacity.
Is there an early access program for retatrutide?
No broad early access program has been announced. Ongoing Phase III trials remain the only legitimate route to receiving retatrutide in the US. ClinicalTrials.gov lists active TRIUMPH sites. Grey-market sources selling retatrutide carry substantial safety risks and are not a substitute for supervised clinical trial access.
This article is for informational and educational purposes only and does not constitute medical or investment advice. Retatrutide is an investigational drug and has not been approved by the FDA, EMA, MHRA, or any other regulatory agency. Approval timelines described here are estimates based on publicly available trial data and standard regulatory review timelines. Actual approval dates depend on trial outcomes, regulatory decisions, and other factors beyond public disclosure. Consult a licensed healthcare provider for medical questions. Peptide File reports on research and does not sell, prescribe, or recommend sources for any compound discussed.